# Immunogenicity & Safety of Bio Farma's Measles-Rubella (MR) Vaccine in Indonesian Infants (Bridging Study)

> **NCT04183114** · PHASE2,PHASE3 · COMPLETED · sponsor: **PT Bio Farma** · enrollment: 540 (actual)

## Conditions studied

- Congenital Rubella Infection
- Measles

## Interventions

- **BIOLOGICAL:** Measles-Rubella vaccine Bio Farma
- **BIOLOGICAL:** MR Vaccine SII

## Key facts

- **NCT ID:** NCT04183114
- **Lead sponsor:** PT Bio Farma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-03
- **Primary completion:** 2019-11-11
- **Final completion:** 2019-11-11
- **Target enrollment:** 540 (ACTUAL)
- **Last updated:** 2019-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04183114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04183114, "Immunogenicity & Safety of Bio Farma's Measles-Rubella (MR) Vaccine in Indonesian Infants (Bridging Study)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04183114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*